article
Women in STEM with Dr Jane Osbourn
Drug Target Review’s Ria Kakkad recently spoke with Dr Jane Osbourn about her experience as a woman in STEM.
List view / Grid view
Drug Discovery Processes
news
Why are women more likely to get Alzheimer’s?
US researchers find that a modified immune protein harming brain connections is much more common in the brains of women with Alzheimer’s, compared to men.
article
On the CRISPR horizon: democratising access to genome-editing technologies
Dr Douglas Ross-Thriepland and Dr David Walter, from the Functional Genomics Centre (FGC) – a joint venture between Cancer Research UK’s (CRUK) drug discovery engine, Cancer Research Horizons, and AstraZeneca – speak to Drug Target Review about their work. The centre’s focus is on genetic screening; cancer models; CRISPR reagent…
article
Activity-directed synthesis: a structure-blind, function-driven molecular discovery approach
An autonomous strategy for molecular discovery could enable the exploration of a far broader chemical space than is possible with conventional approaches. In this article, Niamh Morris from Rosalind Franklin Institute outlines why activity-directed synthesis (ADS) could be the answer, providing examples of how this technique has the potential to…
news
Existing drugs offer potential treatment for AKI
Scottish researchers uncovered that drugs used to treat angina and high blood pressure, could be used to treat AKI.
article
Artificial intelligence-aided screening could boost speed of new drug discovery
Using a natural language-inspired technique, researchers at the University of Central Florida, US, developed an interpretable and generalisable drug target interaction model that achieves 97 percent accuracy in identifying drug candidates for a broad variety of target proteins. Here, Dr Ozlem Ozmen Garibay and Aida Tayebi, who worked on the…
article
How many drug discovery breakthroughs have we missed?
Today’s drug screening methods use one or two types of data. However, disease biology is not replicable by simple screening models because diseases are complex and heterogenous. However, advanced screening methods that process dozens of data sources at one time have uncovered novel hits that have been overlooked across the…
article
Progress towards an RSV vaccine
Despite decades without vaccine development in the respiratory syncytia virus (RSV) space, researchers are now homing in on a potential strategy to protect individuals from this disease. Here, Drug Target Review’s Ria Kakkad spoke with Dr Christy Comeaux, Medical Lead (RSV), Janssen, about the challenges associated with RSV vaccine development and her most promising…
article
Drug Target Review’s top content picks from 2022
In this article, Drug Target Review’s Izzy Wood and Ria Kakkad share some of the most ground-breaking moments from drug discovery this year.
news
The future of drug development: AI tailors artificial DNA
Swedish researchers have designed synthetic DNA that controls a cells’ protein production using AI.
news
Genetic cause of ALS and dementia repaired by RNA-targeting strategy
US scientists have developed a potential medication for the genetic cause of ALS and dementia, that eliminates the mutated segments of RNA.
news
New drug shows promise for fighting both COVID-19 and cancer
US researchers showed that the protein: GRP78, implicated in COVID-19 and cancers, is effected by the new drug HA15.
news
Novel ‘prodrug’ designed to eliminate cancer without harming healthy cells
US researchers discovered in a study in mice that augmented drug eliminates cancer cells without causing toxicity.
article
Five recent CRISPR drug target discoveries
This article highlights five of the latest findings revealed using CRISPR that could be used in the development or design of new therapies.
article
Highlights from PEGS Europe’s Protein & Antibody Engineering Summit
Drug Target Review’s Ria Kakkad recently travelled to Barcelona to attend PEGS Europe’s Protein and Antibody Engineering Summit. In this article, she shares her highlights from the event.